OTC Markets OTCQB - Delayed Quote USD

Theralase Technologies Inc. (TLTFF)

Compare
0.1400 0.0000 (0.00%)
As of September 19 at 4:00 PM EDT. Market Open.
Loading Chart for TLTFF
DELL
  • Previous Close 0.1296
  • Open 0.1296
  • Bid 0.1160 x --
  • Ask 0.1378 x --
  • Day's Range 0.1260 - 0.1308
  • 52 Week Range 0.0800 - 0.2100
  • Volume 27,000
  • Avg. Volume 29,314
  • Market Cap (intraday) 33.995M
  • Beta (5Y Monthly) 1.38
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Nov 27, 2024 - Dec 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

www.theralase.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TLTFF

View More

Performance Overview: TLTFF

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TLTFF
0.00%
S&P/TSX Composite index
13.62%

1-Year Return

TLTFF
22.22%
S&P/TSX Composite index
17.77%

3-Year Return

TLTFF
17.65%
S&P/TSX Composite index
16.21%

5-Year Return

TLTFF
22.22%
S&P/TSX Composite index
41.25%

Compare To: TLTFF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TLTFF

View More

Valuation Measures

Annual
As of 9/19/2024
  • Market Cap

    30.32M

  • Enterprise Value

    30.26M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    45.58

  • Price/Book (mrq)

    27.00

  • Enterprise Value/Revenue

    44.74

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -81.88%

  • Return on Equity (ttm)

    -238.55%

  • Revenue (ttm)

    920.62k

  • Net Income Avi to Common (ttm)

    -4.41M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    428.36k

  • Total Debt/Equity (mrq)

    20.58%

  • Levered Free Cash Flow (ttm)

    -1.61M

Company Insights: TLTFF

People Also Watch